Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

被引：5

作者：

Mansoor, Wasat ^{[1
]}

Kulkarni, Amit S. ^{[2
]}

Kato, Ken ^{[3
]}

Sun, Jong-Mu ^{[4
]}

Shah, Manish A. ^{[5
]}

Enzinger, Peter C. ^{[6
]}

Adenis, Antoine ^{[7
]}

Doi, Toshihiko ^{[8
]}

Kojima, Takashi ^{[9
,10
]}

Metges, Jean-Philippe

Li Zhigang ^{[11
]}

Kim, Sung-Bae ^{[12
]}

Cho, Byoung Chul ^{[13
]}

Sunpaweravong, Patrapim ^{[14
]}

Alsina, Maria ^{[15
,16
]}

Goekkurt, Eray ^{[17
,18
]}

Suryawanshi, Shailaja ^{[2
]}

Norquist, Josephine ^{[2
]}

Shah, Sukrut ^{[2
]}

Shen Lin ^{[19
]}

机构：

[1] Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Merck & Co Inc, Kenilworth, NJ USA

[3] Natl Canc Ctr, Tokyo, Japan

[4] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[5] Weill Cornell Med, New York, NY USA

[6] Dana Farber Canc Inst, Ctr Esophageal & Gastr Canc, Boston, MA 02115 USA

[7] Univ Montpellier, IRCM, INSERM, ICM, Montpellier, France

[8] Natl Canc Ctr Hosp East, Chiba, Japan

[9] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[10] CHU Brest, Inst Cancerol & Hematol ARPEGO Network, Brest, France

[11] Shanghai Chest Hosp Esophageal Dis Ctr, Shanghai, Peoples R China

[12] Asan Med Ctr, Seoul, South Korea

[13] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea

[14] Prince Songkla Univ Hosp, Songkhla, Thailand

[15] Vall dHebron Univ Hosp, Barcelona, Spain

[16] Inst Oncol VCIO, Barcelona, Spain

[17] Hematol Oncol Practice Eppendorf, Hamburg, Germany

[18] Univ Canc Ctr Hamburg, Hamburg, Germany

[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

168

引用

页数：3

共 50 条

[41] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
Youwen Zhu
Kun Liu
Dong Ding
Yangying Zhou
Libo Peng
Advances in Therapy, 2022, 39 : 2614 - 2629
[42] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
Wu, Meiyu
Qin, Shuxia
Wang, Liting
Tan, Chongqing
Peng, Ye
Zeng, Xiaohui
Luo, Xia
Yi, Lidan
Wan, Xiaomin
FRONTIERS IN PHARMACOLOGY, 2022, 13
[43] Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy
Kim, Hye Ryun
Kim, Jee Hung
Rhee, Yumie
Lee, Hosun
Song, Seung Eun
Kim, Chan
Song, Sukyung
Noh, Sung Hoon
Rha, Sun Young
ONCOLOGY, 2016, 90 (05) : 248 - 254
[44] Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Moehler, Markus
Xiao, Hong
Blum, Steven I.
Elimova, Elena
Cella, David
Shitara, Kohei
Ajani, Jaffer A.
Janjigian, Yelena Y.
Garrido, Marcelo
Shen, Lin
Yamaguchi, Kensei
Liu, Tianshu
Schenker, Michael
Kowalyszyn, Ruben
Bragagnoli, Arinilda Campos
Bruges, Ricardo
Montesarchio, Vincenzo
Pazo-Cid, Roberto
Hunter, Shannon
Davenport, Eric
Wang, Jinyi
Kondo, Kaoru
Li, Mingshun
Wyrwicz, Lucjan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (35) : 5388 - +
[45] Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
Llovet, Josep M.
Kudo, Masatoshi
Merle, Philippe
Meyer, Tim
Qin, Shukui
Ikeda, Masafumi
Xu, Ruocai
Edeline, Julien
Ryoo, Baek-Yeol
Ren, Zhenggang
Cheng, Ann-Lii
Galle, Peter R.
Kaneko, Shuichi
Kumada, Hiromitsu
Kamble, Shital
Norquist, Josephine M.
Mody, Kalgi
Dubrovsky, Leonid
Siegel, Abby B.
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 506 - 506
[46] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Jabbour, Salma K.
Lee, Ki Hyeong
Frost, Nicolaj
Kowalski, Dariusz
Breder, Valeriy Vladimirovich
Pollock, Theodore
Reguart, Noemi
Houghton, Baerin
Quantin, Xavier
Keller, Steven M.
Liu, Hong
Piperdi, Bilal
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[47] Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Schadendorf, Dirk
Dummer, Reinhard
Hauschild, Axel
Robert, Caroline
Hamid, Omid
Daud, Adil
van den Eertwegh, Alfons
Cranmer, Lee
O'Day, Steven
Puzanov, Igor
Schachter, Jacob
Blank, Christian
Salama, April
Loquai, Carmen
Mehnert, Janice M.
Hille, Darcy
Ebbinghaus, Scot
Kang, S. Peter
Zhou, Wei
Ribas, Antoni
EUROPEAN JOURNAL OF CANCER, 2016, 67 : 46 - 54
[48] FUNCTIONALITY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS OVER 70 YEARS OF AGE WHO ARE CANDIDATES FOR FIRST-LINE CHEMOTHERAPY TREATMENT
Fiallo, Suarez Dolly Viviana
Carrillo, Quesada Macarena
Lemes, Castellano Angelina
Veiga, Vaz Alvaro
Cruz, Cruz Naylen
Rodriguez, Medina Carlos
Suarez, Cabrera Alexia
Luzardo, Henriquez Hugo
Gonzalvez, Fernandez Joan
Gonzalez, Martin Jesus Maria
Fernandez-Caldas, Gonzalez Paula
De la Iglesia, Inigo Silvia
Gomez, Casares Maria Teresa
Molero, Labarta Teresa
HAEMATOLOGICA, 2020, 105 : 319 - 320
[49] A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer
Cao, Weiguo
Xu, Chun
Lou, Guying
Jiang, Jinsong
Zhao, Shunguang
Geng, Mei
Xi, Wenqi
Li, Hao
Jin, Yening
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (09) : 582 - 587
[50] Phase II study of capecitabine and cisplatin as first-line chemotherapy in patients with advanced esophageal cancer
Hong, Yong S.
Lee, Hyo R.
Hwang, In G.
Lee, Sang C.
Lee, Jeeyun
Park, Joon O.
Park, Young S.
Lim, Ho Y.
Im, Young-Hyuck
Kang, Won K.
ANNALS OF ONCOLOGY, 2006, 17 : 314 - 314

← 1 2 3 4 5 →